Pluristem Therapeutics Inc - ESG Rating & Company Profile powered by AI
The Disclosure score includes 17 UN SDGs including: 'Zero Hunger', 'Reduced Inequalities' and 'Partnerships for the Goals'. Alternative companies in the rating peer group for Pluristem Therapeutics Inc are shown. The webpage is a zero-cost Sustainability analysis for Pluristem Therapeutics Inc.
Pluristem Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 8.0; made up of an environmental score of 8.0, social score of 8.0 and governance score of 8.0.
8.0
High ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Pluristem Therapeutics Inc | 8.0 | High |
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Pluristem Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Pluristem Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Pluristem Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Pluristem Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Pluristem Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Pluristem Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Pluristem Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Pluristem Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Pluristem Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Pluristem Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Pluristem Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Pluristem Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Pluristem Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Pluristem Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Pluristem Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Pluristem Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Pluristem Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Pluristem Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Pluristem Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Pluristem Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Pluristem Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Pluristem Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Pluristem Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Pluristem Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Pluristem Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Pluristem Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Pluristem Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Pluristem Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Pluristem Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Pluristem Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Pluristem Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Pluristem Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Pluristem Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Pluristem Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Pluristem Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Pluristem Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Pluristem Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.